Hebei Changshan Biochem Pharma - Asset Resilience Ratio

Latest as of March 2024: -0.03%

Hebei Changshan Biochem Pharma (300255) has an Asset Resilience Ratio of -0.03% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 300255 total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥-1.20 Million

≈ $-175.21K USD Cash + Short-term Investments

Total Assets

CN¥4.67 Billion

≈ $683.39 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (None–None)

This chart shows how Hebei Changshan Biochem Pharma's Asset Resilience Ratio has changed over time. See Hebei Changshan Biochem Pharma (300255) shareholders funds for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Hebei Changshan Biochem Pharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Hebei Changshan Biochem Pharma.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥-1.20 Million	-0.03%
Total Liquid Assets	CN¥-1.20 Million	-0.03%

Asset Resilience Insights

Limited Liquidity: Hebei Changshan Biochem Pharma maintains only -0.03% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Hebei Changshan Biochem Pharma Industry Peers by Asset Resilience Ratio

Compare Hebei Changshan Biochem Pharma's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Fortress Biotech Inc NASDAQ:FBIO	Biotechnology	11.59%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Apellis Pharmaceuticals Inc NASDAQ:APLS	Biotechnology	0.58%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
BioArctic AB (publ) ST:BIOA-B	Biotechnology	72.35%
Chengzhi Shareholding Co Ltd SHE:000990	Biotechnology	6.73%

Annual Asset Resilience Ratio for Hebei Changshan Biochem Pharma (None–None)

The table below shows the annual Asset Resilience Ratio data for Hebei Changshan Biochem Pharma.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
No yearly data available.

pp = percentage points

About Hebei Changshan Biochem Pharma

SHE:300255 China Biotechnology

Market Cap

$5.56 Billion

CN¥38.01 Billion CNY

Market Cap Rank

#3342 Global

#500 in China

Share Price

CN¥41.36

Change (1 day)

+0.34%

52-Week Range

CN¥23.53 - CN¥69.80

All Time High

CN¥69.80